HMF is recommended over conventional fractionation for patients receiving EBRT across all risk groups, supported by high-quality randomized data demonstrating equivalent oncologic outcomes, toxicity, and quality of life, with shorter treatment duration that may reduce overall treatment burden.
Scott C. Morgan, A. Halthore, Angela Y. Jia et al.· Practical Radiation Oncology· 0 citations
Findings support this approach for appropriately selected patients in routine clinical care for intermediate- and high-risk prostate cancer, as contemporary real-world evidence remains limited.
Z. El Kouzi, M. Rooney, A. Samman et al.· Brachytherapy· 0 citations
IMPORTANCE
The Decipher Prostate Genomic Classifier (GC) and ArteraAI Multimodal Artificial Intelligence (MMAI) platform are widely used prognostic tools for localized prostate cancer (PCa), yet no direct comparison has been performed within the same patient cohort.
METHODS
We sought to evaluate the concordance and p...
Bo-On-Hao Hong, Adeniyi A. Olabumuyi, S. Zhao et al.· Clinical Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.